Human Rabies Immunoglobulin (IM) Industry Research Report 2024
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
According to APO Research, the global Human Rabies Immunoglobulin (IM) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Rabies Immunoglobulin (IM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Rabies Immunoglobulin (IM).
The report will help the Human Rabies Immunoglobulin (IM) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Human Rabies Immunoglobulin (IM) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Rabies Immunoglobulin (IM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Rabies Immunoglobulin (IM) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Rabies Immunoglobulin (IM) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Rabies Immunoglobulin (IM).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Rabies Immunoglobulin (IM) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Rabies Immunoglobulin (IM) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Chapter 11: The main points and conclusions of the report.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
According to APO Research, the global Human Rabies Immunoglobulin (IM) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Rabies Immunoglobulin (IM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Rabies Immunoglobulin (IM).
The report will help the Human Rabies Immunoglobulin (IM) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Human Rabies Immunoglobulin (IM) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Rabies Immunoglobulin (IM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- CSL Behring
- Grifols
- Sanofi
- Sichuan Yuanda Shuyang
- CNBG
- Kamada
- CBPO
- Shuanglin Bio
- Weiguang Bio
- Shanghai RAAS
- Bharat Serum
- VINS
- ERIG
- HRIG
- Category II Exposure
- Category III Exposure
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Rabies Immunoglobulin (IM) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Rabies Immunoglobulin (IM) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Rabies Immunoglobulin (IM).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Rabies Immunoglobulin (IM) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Rabies Immunoglobulin (IM) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Chapter 11: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Human Rabies Immunoglobulin (IM) Market Size (2019-2030) & (US$ Million)
2.2.2 Global Human Rabies Immunoglobulin (IM) Sales (2019-2030)
2.2.3 Global Human Rabies Immunoglobulin (IM) Market Average Price (2019-2030)
2.3 Human Rabies Immunoglobulin (IM) by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
2.3.2 ERIG
2.3.3 HRIG
2.4 Human Rabies Immunoglobulin (IM) by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Category II Exposure
2.4.3 Category III Exposure
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Human Rabies Immunoglobulin (IM) Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Human Rabies Immunoglobulin (IM) Sales (K Units) of Manufacturers (2019-2024)
3.3 Global Human Rabies Immunoglobulin (IM) Revenue of Manufacturers (2019-2024)
3.4 Global Human Rabies Immunoglobulin (IM) Average Price by Manufacturers (2019-2024)
3.5 Global Human Rabies Immunoglobulin (IM) Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Human Rabies Immunoglobulin (IM), Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Human Rabies Immunoglobulin (IM), Product Type & Application
3.8 Global Manufacturers of Human Rabies Immunoglobulin (IM), Date of Enter into This Industry
3.9 Global Human Rabies Immunoglobulin (IM) Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 CSL Behring
4.1.1 CSL Behring Company Information
4.1.2 CSL Behring Business Overview
4.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
4.1.5 CSL Behring Recent Developments
4.2 Grifols
4.2.1 Grifols Company Information
4.2.2 Grifols Business Overview
4.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
4.2.5 Grifols Recent Developments
4.3 Sanofi
4.3.1 Sanofi Company Information
4.3.2 Sanofi Business Overview
4.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
4.3.5 Sanofi Recent Developments
4.4 Sichuan Yuanda Shuyang
4.4.1 Sichuan Yuanda Shuyang Company Information
4.4.2 Sichuan Yuanda Shuyang Business Overview
4.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
4.4.5 Sichuan Yuanda Shuyang Recent Developments
4.5 CNBG
4.5.1 CNBG Company Information
4.5.2 CNBG Business Overview
4.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.5.4 CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
4.5.5 CNBG Recent Developments
4.6 Kamada
4.6.1 Kamada Company Information
4.6.2 Kamada Business Overview
4.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
4.6.5 Kamada Recent Developments
4.7 CBPO
4.7.1 CBPO Company Information
4.7.2 CBPO Business Overview
4.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
4.7.5 CBPO Recent Developments
4.8 Shuanglin Bio
4.8.1 Shuanglin Bio Company Information
4.8.2 Shuanglin Bio Business Overview
4.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
4.8.5 Shuanglin Bio Recent Developments
4.9 Weiguang Bio
4.9.1 Weiguang Bio Company Information
4.9.2 Weiguang Bio Business Overview
4.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
4.9.5 Weiguang Bio Recent Developments
4.10 Shanghai RAAS
4.10.1 Shanghai RAAS Company Information
4.10.2 Shanghai RAAS Business Overview
4.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
4.10.5 Shanghai RAAS Recent Developments
4.11 Bharat Serum
4.11.1 Bharat Serum Company Information
4.11.2 Bharat Serum Business Overview
4.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
4.11.5 Bharat Serum Recent Developments
4.12 VINS
4.12.1 VINS Company Information
4.12.2 VINS Business Overview
4.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.12.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
4.12.5 VINS Recent Developments
5 GLOBAL HUMAN RABIES IMMUNOGLOBULIN (IM) MARKET SCENARIO BY REGION
5.1 Global Human Rabies Immunoglobulin (IM) Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2019-2030
5.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2019-2024
5.2.2 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2025-2030
5.3 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2019-2030
5.3.1 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2019-2024
5.3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2025-2030
5.4 North America Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.4.1 North America Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.4.3 North America Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.5.1 Europe Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.5.3 Europe Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.6.1 Asia Pacific Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.6.3 Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.7.1 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.7.3 Latin America Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.8.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.8.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2019-2030)
6.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2019-2030) & (K Units)
6.1.2 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2019-2030)
6.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2019-2030)
6.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2019-2030)
6.3 Global Human Rabies Immunoglobulin (IM) Price by Type (2019-2030)
7 SEGMENT BY APPLICATION
7.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2019-2030)
7.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2019-2030) & (K Units)
7.1.2 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2019-2030)
7.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2019-2030)
7.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2019-2030) & (US$ Million)
7.2.2 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2019-2030)
7.3 Global Human Rabies Immunoglobulin (IM) Price by Application (2019-2030)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Human Rabies Immunoglobulin (IM) Value Chain Analysis
8.1.1 Human Rabies Immunoglobulin (IM) Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Human Rabies Immunoglobulin (IM) Production Mode & Process
8.2 Human Rabies Immunoglobulin (IM) Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Human Rabies Immunoglobulin (IM) Distributors
8.2.3 Human Rabies Immunoglobulin (IM) Customers
9 GLOBAL HUMAN RABIES IMMUNOGLOBULIN (IM) ANALYZING MARKET DYNAMICS
9.1 Human Rabies Immunoglobulin (IM) Industry Trends
9.2 Human Rabies Immunoglobulin (IM) Industry Drivers
9.3 Human Rabies Immunoglobulin (IM) Industry Opportunities and Challenges
9.4 Human Rabies Immunoglobulin (IM) Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Human Rabies Immunoglobulin (IM) Market Size (2019-2030) & (US$ Million)
2.2.2 Global Human Rabies Immunoglobulin (IM) Sales (2019-2030)
2.2.3 Global Human Rabies Immunoglobulin (IM) Market Average Price (2019-2030)
2.3 Human Rabies Immunoglobulin (IM) by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
2.3.2 ERIG
2.3.3 HRIG
2.4 Human Rabies Immunoglobulin (IM) by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Category II Exposure
2.4.3 Category III Exposure
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Human Rabies Immunoglobulin (IM) Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Human Rabies Immunoglobulin (IM) Sales (K Units) of Manufacturers (2019-2024)
3.3 Global Human Rabies Immunoglobulin (IM) Revenue of Manufacturers (2019-2024)
3.4 Global Human Rabies Immunoglobulin (IM) Average Price by Manufacturers (2019-2024)
3.5 Global Human Rabies Immunoglobulin (IM) Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Human Rabies Immunoglobulin (IM), Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Human Rabies Immunoglobulin (IM), Product Type & Application
3.8 Global Manufacturers of Human Rabies Immunoglobulin (IM), Date of Enter into This Industry
3.9 Global Human Rabies Immunoglobulin (IM) Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 CSL Behring
4.1.1 CSL Behring Company Information
4.1.2 CSL Behring Business Overview
4.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
4.1.5 CSL Behring Recent Developments
4.2 Grifols
4.2.1 Grifols Company Information
4.2.2 Grifols Business Overview
4.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
4.2.5 Grifols Recent Developments
4.3 Sanofi
4.3.1 Sanofi Company Information
4.3.2 Sanofi Business Overview
4.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
4.3.5 Sanofi Recent Developments
4.4 Sichuan Yuanda Shuyang
4.4.1 Sichuan Yuanda Shuyang Company Information
4.4.2 Sichuan Yuanda Shuyang Business Overview
4.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
4.4.5 Sichuan Yuanda Shuyang Recent Developments
4.5 CNBG
4.5.1 CNBG Company Information
4.5.2 CNBG Business Overview
4.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.5.4 CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
4.5.5 CNBG Recent Developments
4.6 Kamada
4.6.1 Kamada Company Information
4.6.2 Kamada Business Overview
4.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
4.6.5 Kamada Recent Developments
4.7 CBPO
4.7.1 CBPO Company Information
4.7.2 CBPO Business Overview
4.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
4.7.5 CBPO Recent Developments
4.8 Shuanglin Bio
4.8.1 Shuanglin Bio Company Information
4.8.2 Shuanglin Bio Business Overview
4.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
4.8.5 Shuanglin Bio Recent Developments
4.9 Weiguang Bio
4.9.1 Weiguang Bio Company Information
4.9.2 Weiguang Bio Business Overview
4.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
4.9.5 Weiguang Bio Recent Developments
4.10 Shanghai RAAS
4.10.1 Shanghai RAAS Company Information
4.10.2 Shanghai RAAS Business Overview
4.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
4.10.5 Shanghai RAAS Recent Developments
4.11 Bharat Serum
4.11.1 Bharat Serum Company Information
4.11.2 Bharat Serum Business Overview
4.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
4.11.5 Bharat Serum Recent Developments
4.12 VINS
4.12.1 VINS Company Information
4.12.2 VINS Business Overview
4.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
4.12.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
4.12.5 VINS Recent Developments
5 GLOBAL HUMAN RABIES IMMUNOGLOBULIN (IM) MARKET SCENARIO BY REGION
5.1 Global Human Rabies Immunoglobulin (IM) Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2019-2030
5.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2019-2024
5.2.2 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2025-2030
5.3 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2019-2030
5.3.1 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2019-2024
5.3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2025-2030
5.4 North America Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.4.1 North America Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.4.3 North America Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.5.1 Europe Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.5.3 Europe Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.6.1 Asia Pacific Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.6.3 Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.7.1 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.7.3 Latin America Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
5.8.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
5.8.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2019-2030)
6.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2019-2030) & (K Units)
6.1.2 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2019-2030)
6.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2019-2030)
6.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2019-2030)
6.3 Global Human Rabies Immunoglobulin (IM) Price by Type (2019-2030)
7 SEGMENT BY APPLICATION
7.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2019-2030)
7.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2019-2030) & (K Units)
7.1.2 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2019-2030)
7.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2019-2030)
7.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2019-2030) & (US$ Million)
7.2.2 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2019-2030)
7.3 Global Human Rabies Immunoglobulin (IM) Price by Application (2019-2030)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Human Rabies Immunoglobulin (IM) Value Chain Analysis
8.1.1 Human Rabies Immunoglobulin (IM) Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Human Rabies Immunoglobulin (IM) Production Mode & Process
8.2 Human Rabies Immunoglobulin (IM) Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Human Rabies Immunoglobulin (IM) Distributors
8.2.3 Human Rabies Immunoglobulin (IM) Customers
9 GLOBAL HUMAN RABIES IMMUNOGLOBULIN (IM) ANALYZING MARKET DYNAMICS
9.1 Human Rabies Immunoglobulin (IM) Industry Trends
9.2 Human Rabies Immunoglobulin (IM) Industry Drivers
9.3 Human Rabies Immunoglobulin (IM) Industry Opportunities and Challenges
9.4 Human Rabies Immunoglobulin (IM) Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
